Tagged with Suresh Mahalingam

An international collaboration of researchers from Griffith University’s Menzies Health Institute Queensland, the University of Tartu, the University of Glasgow and the University of Dundee have developed a COVID-19 laboratory research toolkit for sharing with researchers across the globe. Designed to expedite SARS-CoV-2 vaccine development, drug discovery and fundamental research, particularly in laboratories unaccustomed to […]

Cancer, chronic kidney disease, diabetes and hypertension are the four main comorbidities leading to death from COVID-19, a Griffith University meta-analysis published in mBio has found. The researchers analysed global databases MEDLINE, Scopus, Web of Science and EMBASE of 375,859 participants from 14 countries and found chronic kidney disease was statistically the most prominent comorbidity […]

Griffith University has been named as a Global Virus Network Centre of Excellence, one of three in Australia.

Griffith University researchers have partnered with a leading vaccines manufacturing company based in Hyderabad, India to develop a vaccine for COVID-19.

A new Griffith University study aims to develop drugs to treat alphavirus infection such as Ross River, Chikungunya, O’nyong’nyong and Mayaro viruses which cause debilitating and chronic arthritis. Led by Professor Suresh Mahalingam, head of the Research Group for Emerging Viruses, Inflammation and Therapeutics at Menzies Health Institute Queensland, the $905,080 National Health and Medical […]

Griffith University research projects have received more than $6 million in funding from the National Health and Medical Research Council

The threat of mosquito-borne outbreaks of emerging viruses will be tackled by the newly-established Research Group for Emerging Viruses, Inflammation and Therapeutics.